HIV treatment has come a long way, and today, many people living with HIV are aging, working, raising families, and managing other chronic conditions. That is why the FDA’s approval of IDVYNSO matters. IDVYNSO is a once‑a‑day, two‑drug regimen designed for adults who are already virally suppressed, which offers a tenofovir‑free option that may reduce long‑term medication burden. For many, it is another step toward living well with HIV and not just surviving it.
Black Health Matters spoke with Dr. Debbie Hagins, the medical director of the Coastal CARE Centers in southeast Georgia, about the significance of this approval and what it could mean for people in the United States living with HIV.
Table of Contents
What Is IDVYNSO?
BHM: What makes IDVYNSO different from existing HIV treatment options currently available in the U.S.?
Dr. Hagins: If we take a step back, HIV treatment has evolved quite a bit over time. Initially, we started with a single medication, but we quickly learned that one drug didn’t provide durability and often came with significant side effects.
From there, we moved to two drugs, then three, sometimes even four, and eventually settled into regimens that targeted the virus more effectively at multiple points in its lifecycle. What we’ve learned through that scientific journey is that we need to interrupt the HIV lifecycle in more than one place to maintain control of the virus.
IDYNSO is a two-drug regimen that does just that—it targets two points in the HIV lifecycle. What’s unique is that it does not include an integrase inhibitor, which has been associated with weight gain in some patients. It also avoids certain nucleoside components that have been linked to bone and kidney issues.
Another important piece is that one of its components represents a newer category of HIV medication, which gives us another option in how we approach treatment.
Now that HIV is a chronic, manageable disease, and people are living into their 70s and 80s—and even those born with HIV are now reaching their 30s—we have to think long-term. It’s no longer just about controlling the virus, but also minimizing lifetime exposure to medications and their potential side effects.
The Benefits of a Two-Drug Approach
BHM: From a clinical perspective, what are the potential benefits of simplifying treatment to a two-drug regimen?
Dr. Hagins: One of the biggest advantages is reducing the overall burden on the body. Every medication must be metabolized, and that process requires cellular energy.
We learned years ago that HIV itself is associated with accelerated aging because it creates chronic inflammation. On top of that, some medications can also increase cellular stress. So the question became: Can we effectively treat HIV with fewer medications?
Research showed that one drug wasn’t enough, and even two drugs targeting the same mechanism didn’t provide durable results. But two drugs targeting different points in the lifecycle—that works.
So with a regimen like IDYNSO, we’re minimizing exposure while still maintaining efficacy. This becomes especially important for patients with other health conditions—things like hypertension, diabetes, or those taking multiple medications.
It allows us to treat HIV effectively while being more mindful of the patient’s overall health profile.
Who are the Ideal Patients?
BHM: What type of patient is the ideal candidate for switching to this new regimen?
Dr. Hagins: This particular medication is not for someone who is newly diagnosed.
I think about patients who are aging, particularly those in their 60s, 70s, or even 80s. Many of them have other health conditions like diabetes or hypertension, and they’re often taking multiple medications.
For those individuals, switching to a regimen that avoids known risks—such as kidney or bone complications—can be highly beneficial. It’s really about evaluating each patient and asking, Does this option offer something better for them at this point in their life?
The Long-Term Impact & Quality of Life
BHM: How might this new option impact long-term adherence and quality of life for people living with HIV?
Dr. Hagins: When medications first come out, they’re tested in controlled clinical trials with a limited number of participants. But once they’re widely used, we start to see long-term patterns and side effects emerge.
Over time, we’ve observed issues like bone loss, fat redistribution, and kidney decline with certain HIV treatments. So now, we’re thinking more proactively.
With a medication like IDVYNSO, which avoids some of those known concerns, we can potentially improve long-term outcomes. This is especially important because we’re no longer treating HIV for just a few years—we’re managing it over decades.
So anything we can do early to reduce risk and improve tolerability can have a big impact on a patient’s quality of life down the line.
Disparities & Equity
BHM: Given the disproportionate impact of HIV on Black communities, how could this new option help address existing health disparities?
Dr. Hagins: The medication itself won’t eliminate disparities like stigma or access to care—those are much larger systemic issues. But what it does do is give us another tool.
In the African American community, we see a higher prevalence of HIV and also higher rates of HIV-associated kidney disease, known as HIVAN. That’s something I’ve been very aware of in my practice.
So when we have a medication that avoids components associated with kidney complications, that’s meaningful. It allows us to tailor treatment in a way that may reduce risk for certain patients.
But we also have to remember that treatment success depends on many factors—access to care, trust in the healthcare system, and lifestyle factors all play a role.
Cost & Access
BHM: Do you anticipate cost being a barrier?
Dr. Hagins: Access to medication is always a challenge, regardless of the condition. I don’t have specific information about the cost of this drug, but we know that coverage often depends on insurance formularies, prior authorizations, and whether programs like ADAP include it.
Even patients with good insurance can face hurdles, so we as providers have to advocate for what’s best for our patients and work through that process.
Looking Ahead
BHM: Looking ahead, what more needs to be done to improve outcomes for people living with HIV in the U.S.?
Dr. Hagins: First and foremost, I would say: advocate for yourself. Ask questions. Stay informed.
We want patients to feel comfortable discussing new treatment options with their providers. Not every new medication is right for every person, but it’s important to have that conversation.
At the same time, we’re continuing to see innovation—longer-acting treatments, prevention options, and ongoing work toward a cure.
But the basics are still critical: get tested, know your status, get into care, and stay in care.
Dr. Hagin’s final words were a reminder of both responsibility and hope: ‘Know your status. Protect your health. And live your best life—even with HIV”. With new options like IDVYNSO, the path forward continues to widen.
